PharmaEssentia Corporation (TPE:6446)
Taiwan
· Delayed Price · Currency is TWD 647.00
+24.00 (3.85%)
Apr 29, 2026, 1:30 PM CST
PharmaEssentia Company Description
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan.
Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias.
The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology.
PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
PharmaEssentia Corporation
| Country | Taiwan |
| Founded | 1990 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Ko-Chung Lin |
Contact Details
Address: No. 3, Park Street Taipei, 115 Taiwan | |
| Phone | 886 2 2655 7688 |
| Website | pharmaessentia.com |
Stock Details
| Ticker Symbol | 6446 |
| Exchange | Taiwan Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006446008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ko-Chung Lin Ph.D. | Founder, Chief Executive Officer, Chief Strategy Officer and Director |
| Dr. Ching-Leou Teng Ph.D. | Chairman and Chief Pharmaceutical Officer |
| Chan-Kou Hwang Ph.D. | President, GM and Director |
| Snow Chang | Director of Finance |
| Samuel Lin | Vice President and Head of Business Operations and Strategy |
| Lih-Ling Lin Ph.D. | Chief Scientific Officer |
| Hsing-I Chen | General Counsel |
| Dr. Albert Qin M.D., Ph.D. | Chief Medical Officer |
| Narihisa Miyachi | Head of Japan Medical Affairs |
| Yen-Tung Luan | Chief Operating Officer of Taichung Plant |